Bivision Biomedical Technology Co., Ltd. was established in 2021. It is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment. The company has three major business platforms: targeted radiopharmaceutical screening, radiopharmaceutical conjugation, and radiopharmaceutical clinical transformation. Accelerates translation from preclinical to clinical development using in vivo dynamic imaging evaluation techniques. This type of drug mainly focuses on non-drugable targets, and the company currently has nearly 10 drug targets under development.

       The founding team of the company consists of 4 experts with rich experience in the field of radiopharmaceutical research and development. The above new drug research and development experience, a total of 4 NDA drugs and more than 15 IND project experience. The main members of the company are from internationally renowned companies such as Roche, Eli Lilly, GSK, Siemens and WuXi AppTec. The founder team has a successful experience in the entire process of developing targeted radioligand therapy in the United States from research and development to clinical and marketing. Crystal Nucleus is committed to creating an innovative technology platform for radiopharmaceutical R&D, opening up the entire radiopharmaceutical industry chain, and building an outstanding global radiopharmaceutical enterprise integrating R&D, manufacturing and commercialization.